Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Active Ingredient : Semaglutide, a GLP-1 receptor agonist Mechanism of Action : According to FDA prescribing information, semaglutide works by: Increasing glucose-dependent insulin secretion Decreasing glucagon secretion Slowing gastric emptying Acting on centers in the brain that regulate appetite Clinical Trial Evidence - STEP Program : According to published data from the STEP 1 trial (New England Journal of Medicine, 2021): Study Design : 68-week randomized, double-blind, placebo-controlled trial 1,961 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results : Semaglutide group: Average 14.9% body weight loss (approximately 33 lbs for 220 lb individual) Placebo group: Average 2.4% body weight loss (approximately 5 lbs for 220 lb individual) Difference: 12.4 percentage points (p 3 pounds/week associated with higher risk
Meal timing: They can work with you to plan consistent meal times that optimize your hunger cues and manage other common GI issues, like acid reflux or nausea
Saloni Dattani: What is that
Having adequate muscle mass on your body is also really important if you want to maintain your weight loss long term
Clinicians can increase their chances of success by: Submitting a clear, one-page letter of medical necessity that outlines FDA approval and the patients eligibility Documenting comorbid conditions, prior therapies and BMI trends Utilizing well-organized templates Engaging dedicated staff for navigating the prior authorization process Despite these efforts, barriers remain
US$ 29.19
US$ 27.62
US$ 23.18
US$ 22.49
US$ 22.68
US$ 20.65
